World-Class Research in Queensland
The Translational Science Hub (TSH) unites Sanofi with the Queensland Government, Griffith University, and the University of Queensland in a strategic partnership that connects Queensland researchers with 600 Sanofi scientists at the company's mRNA Centre of Excellence in France and the US.
This cross-continental initiative advances Sanofi's global R&D capabilities as we chase the miracles of science to improve people’s lives and also strengthens Queensland's position as an emerging hub for biomedical innovation and scientific excellence.
Researching next generation vaccines
The TSH is advancing the development of vaccines candidates in areas such as chlamydia
14 research projects will begin in 2025 to optimise mRNA platform technology
7 vaccine trials will be started in Queensland by 2027
The TSH plays an important role in Queensland’s biomedical ecosystem. A focus on medical and vaccine innovation can be a catalyst for economic growth with the creation of highly-skilled jobs, networking and collaboration between researchers, and the shared passion to find new solutions to improve public health.
Dr Iris Depaz (1976 – 2024)
Founder of the Translational Science Hub
Our researchers are internationally recognised at developing new vaccines and therapies, while our Clinical Trial Unit is a leader in testing safety and efficacy. We look forward to the work we undertake here in Queensland with the aim of improving global health outcomes.
Professor Carolyn Evans
Vice Chancellor and President, Griffith University
We have invested in people and facilities to ensure mRNA for pre-clinical research can be developed and produced in Queensland. Collaboration and partnership are at the heart of all great research, and we look forward to making a difference to global health in collaboration with our partners.
Professor Deborah Terry
Vice Chancellor and President, The University of Queensland
Creating jobs and enterprise opportunities
Sanofi’s significant investment in the TSH serves at a catalyst for Queensland’s growing biomedical ecosystem creating new research opportunities, attracting talent, and building local expertise in cutting-edge mRNA technology.
63 jobs (direct and indirect) have already been created in Queensland since 2023
26 clinical trial sites and 7 laboratory partners across Australia have been contracted
IDT Australia has been contracted to support clinical GMP manufacturing of Sanofi mRNA assets
- The University of Queensland and Griffith University are official partners of the TSH
- A preferred partnership agreement with the University of the Sunshine Coast was signed in Q1, 2025
- Sanofi is a funding partner of the BASE facility at the University of Queensland that is establishing a world-leading mRNA laboratory
- PhD scholarship and internship opportunities are being created in Queensland by the TSH
Professor Cameron Simmons joins Sanofi as Head of Translational Science Hub
In this role, Prof. Simmons will lead the strategic direction of the TSH and oversee engagement with local partners.
A globally recognised infectious disease scientist, Prof. Simmons brings a wealth of experience in fundamental research, product development, and public health. He most recently served as Director at the World Mosquito Program, a global leader in
dengue control operating across 14 countries. His academic leadership includes roles at Oxford University, the University of Melbourne, and Monash University, where he led international clinical trials and laboratory research focused on tropical infectious diseases.
Growing the scientific ecosystem in Queensland
Thirteen highly skilled researchers and scientists are now employed by Sanofi in Queensland, with further growth expected in 2024.
The Translational Science Hub has recruited a Head and Deputy Head of Clinical Operations, two Global Clinical Development Strategy Experts, a Project Lead and Coordinator, plus Biostatisticians to explore next generation vaccines using mRNA technology. Dr Iris Depaz also moved into her new position as Managing Director of the Translational Science Hub.
New bases in Brisbane and Gold Coast
Sanofi officially opened research sites at Griffith University Gold Coast and the Translational Research Institute in Brisbane. Researchers will use university infrastructure and technology to better understand mRNA vaccine technology, which will help to optimise the platform to produce better vaccines and expand its use in the development of therapies to treat a variety of diseases.